Neuronetics (NASDAQ:STIM – Get Free Report) and IceCure Medical (NASDAQ:ICCM – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.
Risk & Volatility
Neuronetics has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.
Valuation & Earnings
This table compares Neuronetics and IceCure Medical’s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neuronetics | $72.07 million | 0.33 | -$30.19 million | ($0.96) | -0.82 |
| IceCure Medical | $3.34 million | 8.89 | -$14.65 million | ($0.33) | -1.97 |
Analyst Ratings
This is a summary of recent ratings and price targets for Neuronetics and IceCure Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neuronetics | 0 | 1 | 3 | 0 | 2.75 |
| IceCure Medical | 0 | 0 | 2 | 0 | 3.00 |
Neuronetics currently has a consensus target price of $4.67, indicating a potential upside of 490.64%. IceCure Medical has a consensus target price of $2.70, indicating a potential upside of 315.38%. Given Neuronetics’ higher probable upside, equities research analysts plainly believe Neuronetics is more favorable than IceCure Medical.
Insider and Institutional Ownership
53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 9.8% of Neuronetics shares are owned by insiders. Comparatively, 2.4% of IceCure Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Neuronetics and IceCure Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neuronetics | -45.06% | -109.00% | -31.72% |
| IceCure Medical | -410.22% | -111.27% | -81.41% |
Summary
Neuronetics beats IceCure Medical on 10 of the 14 factors compared between the two stocks.
About Neuronetics
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.
